Natalie McAndrew - Baudax Bio Consultant Officer
Executive
Natalie McAndrew is Consultant Officer of Baudax Bio
Age | 53 |
Phone | 484 395 2440 |
Web | https://www.baudaxbio.com |
Baudax Bio Management Efficiency
The company has return on total asset (ROA) of (1.1493) % which means that it has lost $1.1493 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (47.0421) %, meaning that it created substantial loss on money invested by shareholders. Baudax Bio's management efficiency ratios could be used to measure how well Baudax Bio manages its routine affairs as well as how well it operates its assets and liabilities.Baudax Bio currently holds 7.12 M in liabilities with Debt to Equity (D/E) ratio of 2.26, implying the company greatly relies on financing operations through barrowing. Baudax Bio has a current ratio of 0.52, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Baudax Bio's use of debt, we should always consider it together with its cash and equity.
Similar Executives
Showing other executives | EXECUTIVE Age | ||
Joel Yeung | Virax Biolabs Group | N/A | |
MHS MD | Windtree Therapeutics | 66 | |
Dr MPH | Dermata Therapeutics | 60 | |
Steve Ellul | Biodexa Pharmaceticals | N/A | |
Jose MD | Allarity Therapeutics | 68 | |
Alexander CPA | Allarity Therapeutics | 41 | |
Daniel MBA | Biodexa Pharmaceticals | N/A | |
Sean Proehl | Dermata Therapeutics | N/A | |
Fiona Sharp | Biodexa Pharmaceticals | N/A | |
Maria MBA | Dermata Therapeutics | 74 | |
Mitchell MD | Palisade Bio | 47 | |
Nigel MSc | Virax Biolabs Group | 59 | |
Alexander Epshinsky | Allarity Therapeutics | 42 | |
Clement Monteil | Virax Biolabs Group | N/A | |
Pratap Paruchuru | Windtree Therapeutics | N/A | |
Joerg Heyer | Palisade Bio | N/A | |
George Cox | Windtree Therapeutics | 73 | |
Ryker Willie | Palisade Bio | N/A | |
James Wang | Virax Biolabs Group | N/A | |
Lily Fu | Virax Biolabs Group | N/A | |
Dmitry MD | Biodexa Pharmaceticals | 44 |
Management Performance
Return On Equity | -47.04 | |||
Return On Asset | -1.15 |
Baudax Bio Leadership Team
Elected by the shareholders, the Baudax Bio's board of directors comprises two types of representatives: Baudax Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Baudax. The board's role is to monitor Baudax Bio's management team and ensure that shareholders' interests are well served. Baudax Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Baudax Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
Natalie McAndrew, Consultant Officer | ||
Jillian Dilmore, Corp Controller | ||
Diane Myers, VP Quality | ||
Chan Yong, Chief Director | ||
Geraldine Henwood, CEO President | ||
Mike Choi, Vice Analysis |
Baudax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Baudax Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -47.04 | |||
Return On Asset | -1.15 | |||
Operating Margin | (27.60) % | |||
Current Valuation | 17.72 M | |||
Shares Outstanding | 43.59 M | |||
Shares Owned By Insiders | 0.01 % | |||
Shares Owned By Institutions | 2.68 % | |||
Number Of Shares Shorted | 493.56 K | |||
Price To Earning | 0.03 X | |||
Price To Book | 0.68 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Consideration for investing in Baudax Stock
If you are still planning to invest in Baudax Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Baudax Bio's history and understand the potential risks before investing.
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |